.png){kind=icon}
返回
Chronic Myeloid Leukemia, Version 2.2021
.png){kind=icon}
OA
AI
DOI：10.6004/jnccn.2020.0047.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 (t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase CML.
Keyword:
CHRONIC MYELOGENOUS LEUKEMIA
TYROSINE-KINASE INHIBITORS
CHRONIC-PHASE CML
CLONAL CHROMOSOMAL-ABNORMALITIES
IN-SITU HYBRIDIZATION
PHILADELPHIA-NEGATIVE CELLS
PATIENTS RECEIVING IMATINIB
STANDARD-DOSE IMATINIB
SUBCUTANEOUS OMACETAXINE MEPESUCCINATE
PULMONARY ARTERIAL-HYPERTENSION
期刊
J
IF:
16.4
论文数:
2.8K
被引数:
1.5W
机构
查看更多机构
引用论文
Pre-transplant weight loss predicts inferior outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndrome.png)
OncotargetOAAI
OncotargetIF0
OAAI分享收藏The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overviewLEUKEMIA
LEUKEMIAIF13.4
PREAI
分享收藏New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia慢性粒细胞白血病治疗的新方法和治疗组合
OAAI
OAAI分享收藏Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase OverexpressionCANCER RESEARCHOAAI
CANCER RESEARCHIF16.6
OAAI分享收藏 查看更多内容